Share this page:
Title
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Subject
Description
Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).
Creator
Source
Doria-Rose, Nicole, Mehul S. Suthar, Mat Makowski, Sarah O’Connell, Adrian B. McDermott, Britta Flach, Julie E. Ledgerwood, John R. Mascola, Barney S. Graham, Bob C. Lin, Sijy O’Dell, Stephen D. Schmidt, Alicia T. Widge, Venkata-Viswanadh Edara, Evan J. Anderson, Lilin Lai, Katharine Floyd, Nadine G. Rouphael, Veronika Zarnitsyna, Paul C. Roberts, Mamodikoe Makhene, Wendy Buchanan, Catherine J. Luke, John H. Beigel, Lisa A. Jackson, Kathleen M. Neuzil, Hamilton Bennett, Brett Leav, Jim Albert, and Pratap Kunwar.
Date Last Updated (Year-Month-Day)
2021-04-06
Type
Citation
Doria-Rose, Nicole, Mehul S. Suthar, Mat Makowski, Sarah O’Connell, Adrian B. McDermott, Britta Flach, Julie E. Ledgerwood, John R. Mascola, Barney S. Graham, Bob C. Lin, Sijy O’Dell, Stephen D. Schmidt, Alicia T. Widge, Venkata-Viswanadh Edara, Evan J. Anderson, Lilin Lai, Katharine Floyd, Nadine G. Rouphael, Veronika Zarnitsyna, Paul C. Roberts, Mamodikoe Makhene, Wendy Buchanan, Catherine J. Luke, John H. Beigel, Lisa A. Jackson, Kathleen M. Neuzil, Hamilton Bennett, Brett Leav, Jim Albert, and Pratap Kunwar. 2021. "Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19." New England Journal of Medicine.
Accessibility
Free online on NEJM